DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Exelon (Rivastigmine Tartrate) - Summary




Exelon® (rivastigmine tartrate) is a reversible cholinesterase inhibitor.

Exelon® (rivastigmine tartrate) is indicated for the treatment of mild to moderate dementia of the Alzheimer's type.

See all Exelon indications & dosage >>


Media Articles Related to Exelon (Rivastigmine)

Rivastigmine Improves Gait, Reduces Falls in Parkinson's
Source: Medscape NeurologyHeadlines [2015.07.22]
Rivastigmine improved gait in patients with Parkinson's disease and reduced frequency of falls. Falls are a major concern for patients, and fear of falling can lead to loss of mobility and social isolation.
Medscape Medical News

Positive initial phase 2a study data with ANAVEX 2-73 showing early evidence of improving cognition in patients with Alzheimer's disease
Source: Clinical Trials / Drug Trials News From Medical News Today [2015.07.24]
Anavex Life Sciences Corp. has announced initial positive cognitive data for ANAVEX 2-73, the Company's lead investigational oral treatment for Alzheimer's targeting sigma-1 and muscarinic...

New data presented from phase 1b study of investigational Alzheimer's disease treatment Aducanumab (BIIB037)
Source: Clinical Trials / Drug Trials News From Medical News Today [2015.07.24]
Today Biogen has announced new results from a prespecified interim analysis of PRIME, the Phase 1b placebo-controlled study of aducanumab (BIIB037) in patients with prodromal or mild Alzheimer's...

Novel monoclonal antibodies show promise for Alzheimer's disease treatment
Source: Neurology / Neuroscience News From Medical News Today [2015.07.21]
Parkinson's disease may also be treated with potential therapyScientists at NYU Langone Medical Center's Center for Cognitive Neurology have evidence that monoclonal antibodies they developed may...

One Target, One Treatment? Not for Alzheimer's Disease
Source: Medscape NeurologyHeadlines [2015.07.20]
Promising new therapeutic candidates for Alzheimer's target multiple disease-related proteins and may have benefit in other neurodegenerative diseases.
Medscape Medical News

more news >>

Published Studies Related to Exelon (Rivastigmine)

The ReSPonD trial--rivastigmine to stabilise gait in Parkinson's disease a phase II, randomised, double blind, placebo controlled trial to evaluate the effect of rivastigmine on gait in patients with Parkinson's disease who have fallen. [2013]
BACKGROUND: Gait impairment is common in people with Parkinson's disease. There is a lack of effective interventions to target this debilitating complication and therefore a need to identify new therapeutic options... If effective, it would offer a new therapeutic option to ameliorating gait and cognitive deficits in a population at high risk of falls.

Rivastigmine as alternative treatment for refractory REM behavior disorder in Parkinson's disease. [2012]
disease in whom conventional therapy failed... CONCLUSIONS: The results of this pilot trial need to be confirmed by further

Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy. [2011.12]
OBJECTIVES: The cholinesterase inhibitor rivastigmine is approved for the symptomatic treatment of mild to moderate Alzheimer's disease (AD). This exploratory, hypothesis-forming analysis assessed response to rivastigmine according to severity of dementia at baseline... CONCLUSIONS: Rivastigmine benefits AD patients across dementia stages. Similar to previous cholinesterase inhibitor studies, greatest treatment effects with rivastigmine patch and capsule were seen in patients with more advanced dementia, most likely driven by greater placebo decline in this population. Copyright (c) 2010 John Wiley & Sons, Ltd. Copyright (c) 2010 John Wiley & Sons, Ltd.

Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer's disease: a multicenter, randomized, open-label, parallel-group study. [2011.07]
CONCLUSION: There were no significant differences in tolerability and safety between the treatment groups. The combination therapy of memantine plus rivastigmine patch did not show an advantage over rivastigmine patch monotherapy on efficacy analyses. The sample size for comparing tolerability may have been too small to detect a difference of efficacy between the two groups.

Efficacy of rivastigmine transdermal patch on activities of daily living: item responder analyses. [2011.04]
OBJECTIVE: In Alzheimer's disease (AD), rivastigmine has demonstrated statistically significant efficacy versus placebo on cognition and activities of daily living (ADL). The aim of this retrospective analysis was to further evaluate the treatment effects of rivastigmine on individual ADL items... CONCLUSIONS: These findings suggest that rivastigmine may benefit specific ADL, particularly in patients who are already exhibiting functional impairment. Further research is required to improve understanding of how drugs such as rivastigmine exert their clinical effects. Copyright (c) 2010 John Wiley & Sons, Ltd.

more studies >>

Clinical Trials Related to Exelon (Rivastigmine)

A Double-Blind, Placebo-Controlled Crossover Study of Repeat Rivastigmine (Exelon�) Administration in Young Healthy Male Volunteers [Not yet recruiting]
Rivastigmine is a carbamate, approved by the FDA for the treatment of mild to moderate dementia associated with Alzheimer's and Parkinson's diseases. Studies conducted in the Israel Institute of Biological Research (IIBR) have yielded encouraging results in utilizing rivastigmine pre-treatment as an alternative to pyridostigmine in partially protecting against organophosphate poisoning, particularly protecting the central nervous system.

The target population for this indication may consist of otherwise healthy people (e. g. soldiers). Although the treatment regimen has not been established yet it is assumed, based on animal experiments, that rivastigmine is likely to be administered in repeated doses. In this setting, further evaluation of the drug's effects and pharmacokinetics in young healthy subjects is warranted.

The objectives of this study are: 1) To assess the safety and tolerability of repeated rivastigmine administration (1. 5 mg and 3 mg) in young healthy male volunteers; 2) To determine the pharmacokinetic profile of rivastigmine (1. 5 mg and 3 mg) following a single and multiple dose administrations; 3) To assess the extent of blood ChE inhibition following a single and multiple administrations of rivastigmine and 4) To correlate physiological and behavioral effects with blood rivastigmine concentrations and blood ChE inhibition in these subjects.

This double-blind, placebo-controlled study will be divided in 3 identical periods, preceded with a two-day initial training in performing cognitive performance tests. Each period will consist of in-house confinement for 5 days in which rivastigmine will be administered 5 times at an interval of 12 hours. During each period, each subject will receive either rivastigmine 1. 5 mg X 5, or either rivastigmine 3. 0 mg X 5 or placebo X 5. The treatment in each period will be randomly assigned in a crossover manner. Rivastigmine pharmacokinetics will and acetylcholinesterase inhibition will be assessed after the first and the last dose of each period and will be correlated with physiological and cognitive parameters: performance tests, visual functions, peak airway flow, saliva production (sialometry) and vital signs.

The emergence of adverse events will be monitored throughout the study

Effects of Exercise and Rivastigmine on Quality of Life of Alzheimer's Disease Patients [Recruiting]
The purpose of this study is to determine whether a exercise program when combined with rivastigmine (Exelon patch) drug treatment compared with rivastigmine drug treatment alone would improve quality of life, ability to perform activities of daily living (ADL) and cognition in patients with Alzheimer's disease.


Ho: Rivastigmine drug treatment combined with exercise is not superior to rivastigmine drug treatment to improve quality of life of alzheimer's disease patients.

H1: Rivastigmine drug treatment combined with exercise is superior to rivastigmine drug treatment to improve quality of life of alzheimer's disease patients, with an expectative of 15% of improvement in the quality of life scale measurement

A 12 Week, Multicenter, Open Label Evaluation of Caregiver Preference, Safety and Tolerability of Exelon® Patch (Rivastigmine Transdermal) in Patients With Alzheimer's Disease [Recruiting]
This study is designed to evaluate caregiver preference for Exelon® patch (target patch size 10 cm²) treatment in patients with Alzheimer's disease (MMSE 10-26) who were under cholinesterase inhibitor treatment and experienced adverse event/s in a community setting.

Rivastigmine Prophylaxis in Elderly Patients Undergoing Major Surgery [Recruiting]
The purpose of this study is to determine whether preoperative administration of Rivastigmine prevents the incidence of postoperative delirium in patients undergoing major surgery as well as postoperative cognitive dysfunction.

Rivastigmine in Multiple Sclerosis Patients With Cognitive Impairment [Recruiting]
This study will evaluate the efficacy and safety of 10 cm² rivastigmine patch vs. placebo in cognitively impaired Multiple Sclerosis (MS) patients. Primary objective is the

assessment of cognition by the Selective Reminding Test (SRT) - a subtest of the brief

repeatable battery (BRB) - after titration of 4 weeks and maintenance of 12 weeks. This

double-blind period will be followed by a 52-week open-label treatment phase to assess long-term safety of rivastigmine patch in these patients.

more trials >>

Reports of Suspected Exelon (Rivastigmine) Side Effects

Death (309)Fall (124)Vomiting (86)Pneumonia (78)Cerebrovascular Accident (69)Malaise (63)Dementia Alzheimer's Type (63)Nausea (61)Somnolence (60)Confusional State (57)more >>


Based on a total of 1 ratings/reviews, Exelon has an overall score of 10. The effectiveness score is 10 and the side effect score is 10. The scores are on ten point scale: 10 - best, 1 - worst.

Exelon review by 58 year old female patient

Overall rating:  
Effectiveness:   Highly Effective
Side effects:   No Side Effects
Treatment Info
Condition / reason:   memory
Dosage & duration:   4.5 mg taken twice daily for the period of last 4 years or so
Other conditions:   depression
Other drugs taken:   lexapro namenda trileptal ambien
Reported Results
Benefits:   overall benefits were great. memory has not gotten worse and there is less frustration on my part. Makes my day much better. Although, I have peaks and lows...my lows have been better.
Side effects:   i did not find any side effects.
Comments:   the treatment was for slowing down the progression of memory loss. And it has!

See all Exelon reviews / ratings >>

Page last updated: 2015-07-24

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015